Table II.
Comparison of CADM1 and CADM4 expression at initial diagnosis or surgery in non-pCR and pCR TNBC patients.
| Case | Age (years) | Stage [initial diagnosis, (22)] | PST | Specimen | CADM1 score | CADM4 score |
|---|---|---|---|---|---|---|
| Non-pCR 1 | 45 | IIB | FEC+DTX | CNB | 1 | 1 |
| surgery | 2 and 3 | 2 and 3 | ||||
| Non-pCR 2 | 61 | IIA | FEC+PTX | CNB | 1 | 1 |
| surgery | 2 and 3 | 2 and 3 | ||||
| Non-pCR 3 | 34 | IIA | FEC | CNB | 2 and 3 | 2 and 3 |
| Surgery | 2 and 3 | 2 and 3 | ||||
| Non-pCR 4 | 44 | IIB | FEC+DTX | CNB | 2 and 3 | 2 and 3 |
| Surgery | 2 and 3 | 2 and 3 | ||||
| Non-pCR 5 | 46 | IIA | FEC+DTX | CNB | 2 and 3 | 2 and 3 |
| Surgery | 2 and 3 | 2 and 3 | ||||
| Non-pCR 6 | 54 | IIB | FEC+PTX | CNB | 2 and 3 | 2 and 3 |
| Surgery | 2 and 3 | 2 and 3 | ||||
| Non-pCR 7 | 58 | IIB | FEC+PTX | CNB | 2 and 3 | 2 and 3 |
| Surgery | 2 and 3 | 2 and 3 | ||||
| Non-pCR 8 | 44 | IIIB | FEC | CNB | NA | NA |
| Surgery | 0 | 1 | ||||
| Non-pCR 9 | 33 | IIB | FEC+DTX | CNB | NA | NA |
| Surgery | 1 | 2 and 3 | ||||
| Non-pCR 10 | 78 | IIIB | FEC+DTX | CNB | NA | NA |
| Surgery | 1 | 2 and 3 | ||||
| Non-pCR 11 | 51 | IIIB | FEC+DTX | CNB | NA | NA |
| Surgery | 2 and 3 | 1 | ||||
| Non-pCR 12 | 45 | IIA | FEC+PTX | CNB | 2 and 3 | 2 and 3 |
| Surgery | 2 and 3 | 2 and 3 | ||||
| Non-pCR 13 | 52 | IIB | FEC+PTX | CNB | 2 and 3 | 2 and 3 |
| Surgery | 2 and 3 | 2 and 3 | ||||
| pCR 1 | 40 | IIB | FEC+PTX | CNB | 2 and 3 | 1 |
| Surgery | NA | NA | ||||
| pCR 2 | 50 | IIB | FEC+PTX | CNB | 2 and 3 | 2 and 3 |
| Surgery | NA | NA | ||||
| pCR 3 | 51 | IIB | FEC+DTX | CNB | 2 and 3 | 0 |
| Surgery | NA | NA |
FEC, 5-fluorouracil, epirubicin, and cyclophosphamide; PTX, paclitaxel; DTX, docetaxel; CNB, core needle biopsy; NA, not applicable; TNBC, triple negative breast cancer; pCR, pathological complete response.